Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
|
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [21] Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients COMMENTS
    Link, Michael J.
    Carlson, Matthew L.
    Theodosopoulos, Philip
    Schwartz, Marc S.
    NEUROSURGERY, 2016, 79 (03) : 376 - 377
  • [22] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
    Peyre, Matthieu
    Goutagny, Stephane
    Bah, Alpha
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2013, 72 (06) : 907 - 913
  • [23] Neurofibromatosis Type 2
    Slattery, William H.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2015, 48 (03) : 443 - +
  • [24] Hearing Preservation With the Middle Cranial Fossa Approach for Neurofibromatosis Type 2
    Friedman, Rick A.
    Goddard, John C.
    Wilkinson, Eric P.
    Schwartz, Marc S.
    Slattery, William H., III
    Fayad, Jose N.
    Brackmann, Derald E.
    OTOLOGY & NEUROTOLOGY, 2011, 32 (09) : 1530 - 1537
  • [25] Hearing optimisation in neurofibromatosis type 2: A systematic review
    Lloyd, S. K. W.
    King, A. T.
    Rutherford, A.
    Hammerbeck-Ward, C. L.
    Freeman, S. R. M.
    Mawman, D. J.
    O'Driscoll, M.
    Evans, D. G.
    CLINICAL OTOLARYNGOLOGY, 2017, 42 (06) : 1329 - 1337
  • [26] Hearing changes after diagnosis in neurofibromatosis Type 2
    Masuda, A
    Fisher, LM
    Oppenheimer, TL
    Iqbal, Z
    Slattery, WH
    OTOLOGY & NEUROTOLOGY, 2004, 25 (02) : 150 - 154
  • [27] Management Strategy of Vestibular Schwannoma in Neurofibromatosis Type 2
    Odat, Haitham Ahmad
    Piccirillo, Enrico
    Sequino, Giuliano
    Taibah, Abdelkader
    Sanna, Mario
    OTOLOGY & NEUROTOLOGY, 2011, 32 (07) : 1163 - 1170
  • [28] Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation
    Nicolas -Xavier Bonne
    Rabih Aboukais
    Marc Baroncini
    Audrey Hochart
    Pierre Leblond
    Franck Broly
    Frédérique Dubrulle
    Jean-Paul Lejeune
    Christophe Vincent
    Child's Nervous System, 2016, 32 : 2403 - 2413
  • [29] Management strategies in neurofibromatosis type 2
    Moffat, DA
    Quaranta, N
    Baguley, DM
    Hardy, DG
    Chang, P
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2003, 260 (01) : 12 - 18
  • [30] Pediatric unilateral sensorineural hearing loss: implications and management
    Dornhoffer, James R.
    Dornhoffer, John L.
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2016, 24 (06) : 522 - 528